Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
eisai
capsule
Lenvatinib
Keep in cold place
Delivering To:
Overview
A medication called Lenvima 10mg Capsule is used to treat thyroid, kidney, and liver cancers, among other types of cancer. This drug is a member of the antineoplastic class of cancer-fighting drugs. This medication can be used with or without food. The precise dosage will be determined by your physician. Lenvima 10mg Capsule is used to treat endometrial cancer, liver cancer, kidney cancer, and differentiated thyroid carcinoma, among other cancers. It reduces the size of tumors in individuals with the disease by blocking particular proteins that encourage the growth and metastasis of cancer cells.
Kidney, Thyroid, and Liver cancer
Differentiated Thyroid cancer
Treatment of Kidney Cancer
Liver cancer
Treatment of Endometrial Cancer
Most side effects of Lenalid 10mg Capsule do not require medical attention as they may disappear as your body adjusts to the medicine. If these side effects worsen, consult your doctor immediately.
Cough
Nausea
Sore throat
Vomiting
Weakness
Dizziness Fever
Decrease in white blood cell count
Sleepiness
Confusion
Tremor
Swelling
Respiratory disorder
Bleeding gums
Blood clots
Decreased calcium level in the blood
Your healthcare provider will determine your dose based on your medical condition and individual requirements. Take a Lenvima Capsule as prescribed by your doctor. Do not chew or open the capsule. Take this medicine with or without food.
Lenvima 10mg Capsule contains Lenvatinib, which is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1, VEGFR2, and VEGFR3. Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. After the oral administration, the effect of this medicine can be observed in 1 to 4 hours.
Alcohol
unsafe
It is advisable not to consume alcohol while taking medicine.
Pregnancy
consult your doctor
Do not take Lenvima 10mg Capsule without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not consume Lenvima 10mg Capsule without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
If you miss a dose of Lenvima 10mg Capsule, make sure to contact your healthcare professional before taking the next dose. Do not try to cope with the missed dose by doubling the strength of your next dose.
Lenvima is a medicine that is used to treat certain kinds of cancer, Thyroid cancer, Kidney cancer, and Liver cancer.
This medicine belongs to a class of drugs known as tyrosine kinase inhibitors. It is an anti-cancer medication. This medication works by blocking the nutrient supply, which helps to stop the growth of cancer cells.
Some side effects of Lenvima Capsule are Constipation, bladder pain, diarrhea, bleeding, skin rash, high blood pressure, vomiting, pale skin, muscle pain, dizziness, etc.
This medicine is not recommended for pregnant women.
It is not known whether it is safe or not. It is advised not to consume alcohol while on medication.
Kang, W. et al. (2025). Real‑world safety and effectiveness of LENVIMA® (lenvatinib) in unresectable hepatocellular carcinoma in Korea: post‑marketing study. International Journal of Clinical Practice.
Chiang, C.-H., Yang, J.-D., Liu, W.-L., Chang, F.-Y., Yang, C.-J., Hsu, K.-W., Chiang, I.-T., & Hsu, F.-T. (2025). Mechanistic insights of lenvatinib: Enhancing cisplatin sensitivity, inducing apoptosis, and suppressing metastasis in bladder cancer cells through EGFR/ERK/P38/NF‑κB signaling inactivation.
Fan , F.M et al. (2024). New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma. Drug Discovery Today, 29(8), 104069.
Locati, L. D., et al. (2024). Study confirms Lenvima’s benefits in radioiodine‑refractory differentiated thyroid cancer: real‑world outcomes from Europe and Canada. Annals of Oncology.
Tao, M., Han, J., Shi, J., Liao, H., Wen, K., Wang, W., Mui, S., Li, H., Yan, Y., & Xiao, Z. (2023). Application and resistance mechanisms of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 10, 1069–1083.
